Interim Report Archives - Page 2 of 3

Interim Report Second Quarter 2022

A vision to improve patients’ lives Second quarter 2022 (April–June), Group· Net sales amounted to SEK 0 thousand (0)· Loss before tax amounted to SEK -28,865 thousand (-16,952)· Earnings per share before dilution amounted to SEK -1.40 (-0.89)· Cash flow from operating activities amounted to SEK -24,472 thousand (-12,831)· Cash flow from investing activities amounted to SEK -29,197 […]

An eventful quarter sets the agenda for an intense 2022

First Quarter 2022 (January 1 – March 31), Group Net sales amounted to SEK 0 thousand (0) Loss before tax amounted to SEK -18,934 thousand (-13,912) Earnings per share before dilution amounted to SEK -0.92 (-0.73) Cash flow from operating activities amounted to SEK -27,613 thousand (-11,971) Cash flow from investing activities amounted to SEK […]

Xspray Pharma publishes Q4 Year-End report 2021

”When looking back at Xspray Pharma’s fourth quarter 2021, I see it marked by hope for the future. After the end of the quarter, we reached a significant milestone when the US Food and Drug Administration (FDA) announced that it had agreed to review Xspray Pharma’s first product candidate: Dasynoc, an improved version of dasatinib. […]

Xspray Pharma publishes interim report Q3, January – September 2021

"Since the company's start, the business's focus and communication has been on generic and improved versions of PKIs. Going forward we have, after the end of the reporting period, decided to focus entirely on improved PKIs. In recent years, the value of generics in our models has gradually decreased, while the value of improved drugs […]

Xspray Pharma publishes interim report Q2 , January – June 2021

"We have now shown that our unique technology platform makes it possible to develop amorphous versions of protein kinase inhibitors, or PKIs. With HyNap-Dasa 505(b)(2) and previous studies, we have demonstrated that we can scale up the process and modify formulations to change the uptake of the drug and achieve bioequivalence. This will be of […]

Xspray Pharma publishes Interim Report Q1, January – March 2021

"We are working on a technology platform with potential for many PKI products. The results of the latest studies have set us back, but in a greater perspective it is an unwelcome but minor obstacle. What makes the product platform possible is the unique technology behind the HyNap formulations that can be scaled up. This […]

Xspray Pharma publishes Interim report Q4, January – December 2020

“Our business model is different from traditional drug development. Instead of developing a new drug candidate that will have to undergo Phase I, Phase II and Phase III studies, our technology platform produces amorphous PKI versions that need to demonstrate bioequivalence with already marketed drugs. Several of the marketed PKI:s are highly variable and have […]

Xspray Pharma publishes Interim Report Q3, January – September 2020

”Xspray Pharma is in an eventful phase with several crucial milestones within reach. After completing bioequivalence studies, intensive work is being done on the preparations for the Company's first ANDA application and finding the right partner for HyNap-Dasa”. Per Andersson, CEO Xspray Pharma AB (publ) Significant events during the third quarter, 2020 In August, a […]

Xspray Pharma publishes Interim Report Q2, January – June 2020

"We are in the final development phase of our first protein kinase inhibitor (PKI) project, HyNap-Dasa. HyNap- Dasa has shown good results in previous clinical studies and we are looking forward to seeing positive result this time as well. We have ahead of us an exciting and eventful second half of the year, with the […]

Xspray Pharma publishes Interim report Q1, January – March 2020

“This year is an important year for Xspray. I expect that the amorphous material provided by our unique production facility will provide positive clinical data, which is a prerequisite for us to apply for market approval for HyNap-Dasa in the U.S. This means that we together with a partner who either buys or licenses the […]